Greensboro, NC, United States of America

Rongyuan Xie

This inventor holds 10 USPTO granted patents and 5 published patent applications, plus 2 CIPO patents and 2 EPO patents. Top assignees: Transtech Pharma, Inc., High Point Pharmaceuticals, LLC, Vtv Therapeutics LLC. Active years: 2005-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Rongyuan Xie. Retrieved from https://idiyas.com/inventor/rongyuan-xie

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10 (Patent Applications = 5)

% Patents Active = 50.0

CIPO Patents = 2

EPO Patents = 2 (Patent Applications = 4)

Average Co-Inventor Count = 5.5

ph-index = 3

Forward Citations = 29(Granted Patents)

Location History:

High Point, NC (US) (2005)
Greensboro, NC (US) (2010 - 2019)

Company Filing History:

6 out of 49

Transtech Pharma, Inc.

patents

2 out of 50

High Point Pharmaceuticals, LLC

Years Active: 2005-2019

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10363241 - Substituted imidazole derivatives and methods of use thereof (2019-07-30),

2. 9598375 - Substituted imidazole derivatives and methods of use thereof (2017-03-21),

3. 9045461 - Phenyl-heteroaryl derivatives and methods of use thereof (2015-06-02),

4. 8741900 - Phenyl-heteroaryl derivatives and methods of use thereof (2014-06-03),

5. 8580833 - Substituted imidazole derivatives and methods of use thereof (2013-11-12),

6. 8450354 - Substituted imidazo[1,2-b]pyridazine derivatives, pharmaceutical compositions, and methods of use as β-secretase inhibitors (2013-05-28),

7. 8404731 - Substituted imidazole derivatives, compositions, and methods of use as PTPase inhibitors (2013-03-26),

8. 8350039 - Substituted isoquinoline derivatives, pharmaceutical compositions, and methods of use as beta-secretase inhibitors (2013-01-08),

9. 7723369 - Substituted imidazole derivatives, compositions, and methods of use as PTPase inhibitors (2010-05-25),

10. 6933303 - Heteroaryl-fused nitrogen heterocycles as therapeutic agents (2005-08-23),

Title: Inventor Rongyuan Xie: Advancements in Pharmaceutical Innovations

Introduction

Rongyuan Xie, based in Greensboro, NC, is a prominent inventor known for his contributions to the field of pharmaceuticals. With a total of ten patents to his name, his work has significantly impacted the development of new therapies, particularly in the area of neurodegenerative diseases.

Latest Patents

Among his latest innovations are two notable patents focused on substituted imidazole derivatives. The first patent discusses intermediates for synthesizing compounds described by Formula (I) and their pharmaceutically acceptable salts. The second highlights the imidazole derivatives of the same formula, underscoring their potential use in the treatment of Alzheimer's Disease. These advancements are crucial, offering hope for improved therapeutic options for patients suffering from this debilitating condition.

Career Highlights

Rongyuan Xie has made significant strides in his career, especially through his work with notable pharmaceutical companies such as Transtech Pharma, Inc. and High Point Pharmaceuticals, LLC. His contributions to these organizations have played a vital role in the advancement of innovative drugs and therapeutic methodologies.

Collaborations

Throughout his career, Rongyuan has collaborated with esteemed colleagues, including Robert Carl Andrews and Raju Bore Gowda. These partnerships have been essential in driving research efforts and enhancing the impact of their collective innovations within the pharmaceutical sector.

Conclusion

Rongyuan Xie exemplifies the spirit of innovation in pharmaceutical research. His ten patents reflect a deep commitment to improving healthcare outcomes, particularly for diseases like Alzheimer's. As the industry continues to evolve, the contributions of inventors like Xie will remain pivotal in shaping the future of medicine.

Profile summary based on public USPTO records.